9 April 2024 (Beijing Time), Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment …
Groundbreaking New Blood Test Offers Early Pancreatic Cancer Diagnosis Study Says
As reported in today’s issue of the journal Metabolites, researchers at Metabolomycs, a California-based biotechnology company, for the …
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been …
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA 
Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) …
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for …
